Virginijus Siksnys

USPTO Granted Patents = 12 (Patent Applications = 12)

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 4 (Patent Applications = 8)

Average Co-Inventor Count = 3.9

ph-index = 5

Forward Citations = 224(Granted Patents)

Company Filing History:

7 out of 6,615

Pioneer Hi-bred International, Inc.

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12365888 - CRISPR-Cas systems for genome editing (2025-07-22),

2. 12215364 - CRISPR-cas systems for genome editing (2025-02-04),

3. 12084676 - Cas9 orthologs (2024-09-10),

4. 12065689 - Methods for the identification and characterization of double-strand break sites and compositions and uses thereof (2024-08-20),

5. 11807878 - CRISPR-Cas systems for genome editing (2023-11-07),

6. 11555187 - RNA-directed DNA cleavage by the Cas9-crRNA complex (2023-01-17),

7. 11371050 - Rapid characterization of Cas endonuclease systems, PAM sequences and guide RNA elements (2022-06-28),

8. 11274317 - Targeted RNA knockdown and knockout by type III-A Csm complexes (2022-03-15),

9. 10934536 - CRISPR-CAS systems for genome editing (2021-03-02),

10. 10844378 - RNA-directed DNA cleavage by the Cas9-crRNA complex (2020-11-24),

11. 10385336 - Programmable RNA shredding by the type III-A CRISPR-Cas system of (2019-08-20),

12. 9637739 - RNA-directed DNA cleavage by the Cas9-crRNA complex (2017-05-02),

Title: The Innovative Journey of Virginijus Siksnys

Introduction

Virginijus Siksnys, an esteemed inventor based in Vilnius, Lithuania, has made significant contributions to the field of genome editing. With a portfolio of 12 patents, he has emerged as a key figure in the advancement of CRISPR technology, paving the way for groundbreaking innovations in genetic research.

Latest Patents

Among his notable inventions is a series of patents centered on CRISPR-Cas systems for genome editing. His latest patents detail compositions and methods for modifying target sequences within the genome of a cell using a novel Cas endonuclease. These methods utilize a guide polynucleotide/endonuclease system, providing an efficient tool for altering genetic sequences. Additionally, his work includes innovative endonuclease systems that can involve guide polynucleotide/endonuclease systems comprising at least one endonuclease, which may be linked to additional protein subunits. His compositions also focus on direct delivery methods of endonucleases in the form of ribonucleotide proteins, showcasing his commitment to practical and applicable solutions in genetic editing.

Career Highlights

Virginijus Siksnys has had a remarkable career, with roles at premier institutions, notably Pioneer Hi-Bred International, Inc. and Vilnius University. His experience at these organizations has contributed to his deep understanding and expertise in genetic engineering and biotechnology.

Collaborations

Throughout his career, he has collaborated with esteemed professionals in the field, including Joshua K. Young and Zhenglin Hou. These partnerships have led to a rich exchange of ideas and further innovations in DNA modification technologies.

Conclusion

Virginijus Siksnys continues to be a prominent figure in the realm of genome editing, with his innovative research and developments in CRISPR technology solidifying his legacy. His contributions not only enhance scientific understanding but also open new pathways for therapeutic advancements, making him an inspiring inventor in modern science.

This text is generated by artificial intelligence and may not be accurate.